Browse
Submit Data
Databases
API
Help

Dataset Information

24 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

ABSTRACT: This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors

DISEASE(S): Carcinoma,Triple Negative Breast Neoplasms,Non Small Cell Lung Cancer,Carcinoma, Renal Cell,Colorectal Cancer Metastatic,Colorectal Neoplasms,Triple Negative Breast Cancer,Bladder Cancer,Gastroesophageal Cancer,Renal Cell Carcinoma,Breast Neoplasms,Msi-h

PROVIDER: 2292184 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Project description:To address the role of immune dysregulation in AML, we conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg IV on day 14 to examine whether programmed death-1 inhibition improves clinical responses in relapsed/refractory (R/R) AML. Overall responders could receive pembrolizumab maintenance up to two years. Among thirty-seven patients enrolled, the overall response rate, composite complete remission rate (CRc; primary endpoint), and median overall survival (OS) were 46%, 38% and 11.1 months, respectively. Patients with refractory/early relapse and those receiving treatment as first salvage had encouraging outcomes (median OS 13.2 and 11.3 months, respectively). Grade >3 immune-related adverse events were rare (14%) and self-limiting. Patients who achieved CRc had a higher frequency of progenitor exhausted CD8+ T-cells in the bone marrow prior to treatment and a non-significant increase in baseline T-cell diversity.

2021-09-09 | GSE183415 | GEO

Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Project description:Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

| PRJNA760534 | ENA

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Project description:Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

| PRJNA800756 | ENA

Epigenetic reprogramming in relapsed childhood ALL

2012-06-12 | GSE34880 | GEO

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Project description:This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

| 2099453 | ecrin-mdr-crc

Epigenetic reprogramming in relapsed childhood ALL

Project description:Reversing gene expression signatures in relapsed patient may restore chemosensitivity. We demonstrate that the histone deacetylase inhibitor vorinostat not only reprograms the aberrant gene expression profile of relapsed blasts but is synergistic when applied prior to chemotherapy in primary patient samples and leukemia cell lines Primary patient samples were collected from patients treated at the New York University Medical Center and from the Childrenâs Oncology Group (COG) cell bank,RNA was isolated from three primary patient samples and three B-lineage leukemia cell lines with or without treatment with vorinostat for 24 hours.

2012-06-11 | E-GEOD-34880 | biostudies-arrayexpress

Distinct Transcriptional Landscapes Identified by Radiographic Response in Metastatic Triple-Negative Breast Cancer Treated with Carboplatin, Nab-Paclitaxel, and Pembrolizumab in a Single-Arm Phase II Trial

Project description:A single arm, Phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, and identify pathologic and transcriptomic correlates of response to therapy.

2023-10-19 | GSE241876 | GEO

Mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy

Project description:This study identifies mechanisms of response to immune checkpoint inhibition in mouse models of triple negative breast cancer.

2019-11-13 | GSE136206 | GEO

scRNA-seq of human PBMCs and tumor-infiltrated lymphocytes from melanoma patients analysed prior to checkpoint inhibitor treatment

Project description:We performed single-cell RNA-sequencing of tumor immune infiltrates and matched peripheral blood mononuclear cells of checkpoint inhibitor (CPI)-naive stage III-IV metastatic melanoma patients. After sample collection, the same patients received CPI-treatment and their response was assessed.

2024-04-08 | E-MTAB-13770 | biostudies-arrayexpress

Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

Project description:Comparative cardiac transcriptomics of immune checkpoint inhibitor induced myocarditis

| PRJEB37155 | ENA